Gene therapy holds great promise for new treatments for many diseases. Despite great pre-clinical successes, few gene therapy treatments have been effective in patients. In this grant application, is proposed a new type of gene therapy system, namely morpholino-nanoparticles. Morpholinos are highly effective for suppressing gene expression and, notably, for suppressing microRNA function. The nanoparticles used will possess the following features: morpholinos attached using a dithiol bond that will be cleaved in endosomes;a polymer coating that can disrupt endosomes for morpholino release into the cytoplasm;PEG chains to allow a long circulation half-life;galactose targeting to hepatocytes;an iron core for MRI and TEM detection;and a fluorophore for fluorescence techniques. The iron oxide and fluorophore components of the nanoparticle allow for a theranostic

Public Health Relevance

Heart disease is the number one killer in the USA, and also leads to poor quality of life for those who suffer from it. High cholesterol levels lead to a higher likelihood a heart attack. While the class of drugs known as statins has been successful for lowering the cholesterol levels of many patients, there are still large populations for whom cholesterol levels are too high. In this application are proposed new methods for reducing cholesterol levels where nanoparticles deliver drugs called morpholinos that will shut down cholesterol production. We will focus on developing these morpholino-nanoparticle systems and evaluating their potential to reduce cholesterol levels.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Career Transition Award (K99)
Project #
5K99EB012165-02
Application #
8120348
Study Section
Special Emphasis Panel (ZEB1-OSR-C (M1))
Program Officer
Erim, Zeynep
Project Start
2010-08-01
Project End
2012-06-30
Budget Start
2011-08-01
Budget End
2012-06-30
Support Year
2
Fiscal Year
2011
Total Cost
$89,364
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Duivenvoorden, Raphaƫl; Tang, Jun; Cormode, David P et al. (2014) A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat Commun 5:3065
Barazza, Alessandra; Blachford, Courtney; Even-Or, Orli et al. (2013) The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques. Bioconjug Chem 24:1039-48
Chen, Wei; Cormode, David P; Vengrenyuk, Yuliya et al. (2013) Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression. JACC Cardiovasc Imaging 6:373-84
Gianella, Anita; Mieszawska, Aneta J; Hoeben, Freek J M et al. (2013) Synthesis and in vitro evaluation of a multifunctional and surface-switchable nanoemulsion platform. Chem Commun (Camb) 49:9392-4
Galper, Merav Weill; Saung, May Tun; Fuster, Valentin et al. (2012) Effect of computed tomography scanning parameters on gold nanoparticle and iodine contrast. Invest Radiol 47:475-81
van Tilborg, Geralda A F; Cormode, David P; Jarzyna, Peter A et al. (2012) Nanoclusters of iron oxide: effect of core composition on structure, biocompatibility, and cell labeling efficacy. Bioconjug Chem 23:941-50
Hajjar, Roger J; Cormode, David P (2012) Tracking cell therapy: bioluminescence lighting the way. JACC Cardiovasc Imaging 5:56-8
Mieszawska, Aneta J; Gianella, Anita; Cormode, David P et al. (2012) Engineering of lipid-coated PLGA nanoparticles with a tunable payload of diagnostically active nanocrystals for medical imaging. Chem Commun (Camb) 48:5835-7
Skajaa, Torjus; Cormode, David P; Jarzyna, Peter A et al. (2011) The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. Biomaterials 32:206-13
Chen, Wei; Cormode, David P; Fayad, Zahi A et al. (2011) Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol 3:146-161

Showing the most recent 10 out of 15 publications